Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prizloncabtagene autoleucel in relapsed/refractory large B-cell lymphoma
NCT05800977Phase 2Recruiting
- Sponsor
- AbelZeta
- Start
- Feb 2023
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of prizloncabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by AbelZeta. Primary endpoints: Treatment-emergent Adverse Events at 90 days, Recommended Phase 2 Dose at 3 months and 1 more. Started Feb 2023; status: recruiting.
02
Drugs
prizloncabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05800977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800977.